Since FDA approval of the first ICI, ipilimumab, in 2011, a growing portfolio of monoclonal antibodies targeting the CTLA-4 and PD-1/PD-L1 pathways has emerged, which purport therapeutic advantage over a broad spectrum of cancers (Table 1). This evidence concerns the gene CD274 and cancer.